Clinical Trials Browser

Interventional × Ovarian Neoplasms × Drug Therapy × Clear all

NCT04575935 2026-03-05

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07033819 2026-02-27

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

Phase 2 Recruiting

Ovarian Neoplasms

NCT03943173 2026-02-25

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

Phase EARLY_PHASE1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02327078 2025-08-14

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Phase 1/2 Completed

307 enrolled 27 charts

CNSDermatologicGastrointestinalGynecologicHead & NeckLymphoidThoracic

Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT06602063 2025-06-27

Surgery for Relapsed Ovarian Cancer in Precision

Phase 1/2 Not yet recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06990503 2025-05-25

SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 3 Not yet recruiting

Ovarian Neoplasms

NCT03353831 2025-04-06

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Phase 3 Completed

Ovarian Neoplasms

NCT06560112 2025-03-12

An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms

NCT05704621 2025-03-06

SOCCER-P

Phase 2 Recruiting

Neoplasms, Ovarian Neoplasms

NCT03314740 2025-01-10

BAROCCO

Phase 2 Completed

123 enrolled 14 charts

Ovarian Neoplasms

NCT05183984 2024-10-16

NIRVANA-1

Phase 2 Recruiting

Ovarian Neoplasms

NCT03949283 2024-08-22

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT05684731 2024-08-13

K19017-004

Phase 1 Recruiting

Ovarian Neoplasms

NCT03539406 2024-08-09

INTRO

Phase 1 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06376604 2024-04-19

Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies

Phase NA Recruiting

Intermittent Fasting, Ovarian Neoplasms

NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Cholangiocarcinoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Hyper-IgM Immunodeficiency Syndrome

NCT05143970 2024-03-20

CHANCES

Phase 1 Unknown

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04201561 2023-06-26

SELENIUM

Phase 3 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peripheral Nervous System Diseases

NCT02855944 2023-06-09

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Phase 3 Completed

349 enrolled 29 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT03642132 2023-04-06

JAVELIN OVARIAN PARP100

Phase 3 Terminated

79 enrolled 18 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02759588 2023-01-05

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Phase 1/2 Completed

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Poxviridae Infections, Vaccinia, Virus Diseases

NCT05607329 2022-11-07

Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial

Phase NA Recruiting

Ovarian Neoplasms

NCT01809379 2022-07-08

Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer

Phase 2 Completed

Ovarian Neoplasms, Recurrence

NCT04795596 2022-04-15

Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers

Phase 2/3 Withdrawn

Ovarian Neoplasms

NCT05170594 2021-12-28

A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer

Phase 2 Unknown

Ovarian Neoplasms

NCT05059782 2021-09-28

Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer

Phase NA Unknown

Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Recurrence

NCT04747717 2021-02-11

Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer

Phase NA Unknown

Ovarian Neoplasms

NCT02107950 2018-08-15

Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT01684878 2017-05-23

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

Phase 3 Completed

208 enrolled 19 charts

Ovarian Neoplasms

NCT00318370 2015-09-09

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Phase 2 Completed

58 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00002895 2013-12-04

Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00003695 2013-12-04

Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer

Phase 3 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00019461 2013-06-20

Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00005046 2013-05-27

Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00003358 2013-01-16

Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00243685 2012-01-26

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

Phase 2/3 Completed

BreastGynecologicSarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma

NCT00157560 2008-01-03

Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma

Phase 2 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms